51 results about "Carboplatin" patented technology

The invention discloses an enantiokaurane compound with antitumor activity as well as a preparation method and application of the enantiokaurane compound. According to the present invention, chemical components of Western African plant I.trichantha tubers are deeply studied, and a variety of chromatographic separation methods such as macroporous resin, silica gel resin, medium pressure preparation-MCI column, gel normal pressure column and semi-preparative high performance liquid chromatography are combined to separate to obtain one enantiokaurane new compound Trichanthone B; experiments show that the compound obtained through separation has a good inhibition effect on an MIA PaCa-2 pancreatic cancer cell line and an A549 lung cancer cell line, and IC50 of the compound on the MIA PaCa-2 pancreatic cancer cell line reaches a nanomole level; the effect of the compound is stronger than that of positive drugs 5-fluorouracil and carboplatin, and the compound has the potential of being developed into new drugs for resisting pancreatic cancer and lung cancer.

The invention belongs to the technical field of biomedicine, and particularly relates to application of SOX4 in preparation of a preparation for improving sensitivity of cervical cancer to chemotherapeutic drugs, and the amino acid sequence of the SOX4 is as shown in SEQ ID NO.1. An SOX4 knocked-down stable transfection cell line is constructed in a Hela cell, then carboplatin and oxaliplatin are respectively added into the SOX4 knocked-down Hela cell, and the IC50 of the cell to the carboplatin and the oxaliplatin is obviously reduced, which indicates that the sensitivity of the Hela cell to the carboplatin and the oxaliplatin is enhanced by SOX4 knock-down. By reducing the expression of SOX4, the sensitivity of Hela cells to chemotherapeutic drugs such as carboplatin and oxaliplatin is enhanced, so that the treatment effect of the chemotherapeutic drugs such as carboplatin and oxaliplatin is effectively improved. Results of the invention prove that inhibition of SOX4 is beneficial to recovery of chemosensitivity of cervical cancer cells to drugs such as carboplatin and oxaliplatin, and a new treatment strategy is provided for treatment of drug-resistant cervical cancer.

Provided include methods, compositions and kits for treating ovarian cancer (e.g., platinum-resistant ovarian cancer) in a subject. The method can comprise administration of a combination of a PLK1 inhibitor and a DNA-damaging agent (e.g., carboplatin or gemcitabine) to the subject in a manner sufficient to inhibit progression of the cancer.

The invention belongs to the field of anti-tumor compounds, and particularly relates to a preparation method of carboplatin-unsaturated fatty acid liposome, which comprises the following steps: S1, preparing lecithin into a lecithin solution; preparing unsaturated fatty acid into a fatty acid solution; preparing carboplatin into a carboplatin solution; s2, adding a lecithin solution and a fatty acid solution into an eggplant-shaped bottle, then adding chloroform or dichloromethane, uniformly mixing, and carrying out rotary evaporation to obtain a phospholipid membrane; s3, taking and preheating a carboplatin solution, adding the carboplatin solution into the phospholipid membrane after preheating, and performing ultrasonic hydration to obtain a liposome solution; s4, performing ultrasonic crushing on the liposome solution; and S5, filtering the ultrasonically crushed liposome solution to obtain the liposome. The invention also discloses an application of the carboplatin-unsaturated fatty acid liposome prepared by the preparation method in preparation of antitumor drugs. The problem that in the prior art, the curative effect and safety of a carboplatin drug are difficult to consider at the same time can be solved, and metastatic tumor cells can be effectively inhibited at low drug concentration.

The invention provides a compound of carboplatin and 1, 1-cyclobutane dicarboxylic acid and a detection method of the compound. A nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of the carboplatin and 1, 1-cyclobutane dicarboxylic acid eutectic compound in a D-(+)-glucose heavy water solution with the mass fraction of 5%, a nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of carboplatin in a 1.2. 3. 4-cyclobutane tetracarboxylic acid heavy water solution with the mass fraction of 2%, and a 1, 1-cyclobutane dicarboxylic acid eutectic compound with the mass fraction of 1, 1-cyclobutane dicarboxylic acid are measured. A nuclear magnetic resonance hydrogen spectrum and a nuclear magnetic resonance carbon spectrum of carboplatin and 1, 1-cyclobutane dicarboxylic acid in a D-(+)-glucose heavy water solution with the mass fraction of 5% are analyzed, and the structure of the carboplatin and 1, 1-cyclobutane dicarboxylic acid eutectic compound in water is determined by analyzing the chemical shift change of characteristic carbon atoms in the nuclear magnetic resonance carbon spectrum.

The present invention provides a WRN inhibitor for use in the treatment of cancer, in particular microsatellite instability-high (MSI- H) or mismatch repair deficient (dMMR) cancer, wherein the treatment further comprises administration of: A. an ionising radiation-based therapy selected from: i) external beam radiation, ii) brachytherapy and Hi) a radiopharmaceutical, or B. carboplatin and paclitaxel; The WRN inhibitor is a compound of formula (1g) or compound C : Formula (C).

The invention belongs to the technical field of biological medicine, and provides a nano-carrier drug delivery system loaded with carboplatin as well as a preparation method and application of the nano-carrier drug delivery system. The preparation method comprises the following steps: (1) dissolving AZ-COOH, EDCI and HOBT in DMSO, and activating to obtain a first mixed solution; dSPE-PEG2000-NH2 and TEA are dissolved in DMSO (dimethyl sulfoxide), and a second mixed solution is obtained after stirring; dropwise adding the first mixed solution into the second mixed solution, reacting, dialyzing, and drying to obtain a nano-carrier DSPE-PEG-CAI; (2) dissolving the nano carrier DSPE-PEG-CAI and carboplatin in an organic solvent to obtain an organic phase; adding ultrapure water, continuously performing ultrasonic treatment, and volatilizing the organic solvent to obtain a water phase; and carrying out aqueous phase dialysis, and filtering to obtain a nano carboplatin DSPE-PEG-CAI-CBP aqueous solution. The carboplatin-loaded nano-carrier drug delivery system provided by the invention can improve the targeting property and intracellular enrichment degree of drugs, and passes through a biological barrier established by a tumor microenvironment, so that the targeting selectivity to triple negative breast cancer cells is enhanced, and the side effects of carboplatin treatment are reduced.

The present invention relates to methods of treating B-cell lymphomas, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering an anti-CD20 / anti-CD3 bispecific antibody (e.g., glofitamab) and in combination with one or more anti-CD20 antibodies (e.g., obinutuzumab and / or rituximab) and one or more chemotherapeutic agents selected from ifosfamide, carboplatin, and / or etoposide.

Described herein are methods of treating a MTAP-null lung cancer in a patient comprising administering to the patient a PRMT5 inhibitor and an anti-PD1 antibody, optionally in combination with carboplatin and either paclitaxel or pemetrexed. Further described herein are methods of treating a MTAP-null cancer in a patient also suffering from brain metastases comprising administering to the patient a PRMT5 inhibitor.

The application relates to application of miRNA as a target point in preparation of a drug for treating non-small cell lung cancer, and belongs to the biomedical technology field. The application provides application of miR-423-5p or miR-135a-5p as a target point in preparation of a drug for treating non-small cell lung cancer, specifically, application of an expression inhibitor of miR-423-5p or an overexpression reagent of miR-135a-5p in preparation of a drug for treating non-small cell lung cancer. The expression inhibitor of miR-423-5p or the overexpression reagent of miR-135a-5p in the application can cause the proliferation and migration ability of representative cells A549 and NCI-H1703 of non-small cell lung cancer to decrease and promote the apoptosis of the cells, and combined treatment of tumor chemotherapy drugs cisplatin or carboplatin can enhance the growth inhibition on the above two cell lines.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The invention relates to the technical field of biological medicine, and discloses an activated cis-platinum reversible coordination complex, coordination nano-micelles thereof and application of the activated cis-platinum reversible coordination complex and the coordination nano-micelles. The activated cis-platinum reversible coordination complex is a complex formed by a coordination material and a metal platinum drug or an activated molecule thereof or a derivative thereof, and the coordination ratio of a coordination group in the coordination material to the metal platinum drug or the activated molecule thereof or the derivative thereof is less than or equal to 2: 1; the coordination material is a coordination phospholipid-like material or a coordination polymer material; the metal platinum medicine or the activated molecule or the derivative thereof is cis-platinum, carboplatin, lobaplatin, epithiaplatin, nedaplatin, oxaliplatin or the activated molecule or the derivative thereof. According to the activated cisplatin reversible coordination complex and the coordination nano-micelle and application thereof, the coordination nano-micelle not only can realize cisplatin controlled release regulated by iron ions, but also can reduce ferroptosis of renal tubular cells and related renal cells by chelating the iron ions, so that the renal toxicity of the cisplatin is efficiently inhibited, and the application value is wide.

The invention provides an application of CLCA2 or a carrier for overexpressing the CLCA2 or a lentivirus for overexpressing the CLCA2 in preparation of a medicine for treating triple negative breast cancer. The invention firstly points out that the CLCA2 is a regulatory factor for promoting the apoptosis of triple negative breast cancer cells, and compared with a wild mouse, the mouse overexpressing the CLCA2 shows that the tumor progression of the triple negative breast cancer is obviously inhibited. It is proposed for the first time that the drug target CLCA2 can regulate and control cell apoptosis of the triple-negative breast cancer, the sensitivity of platinum chemotherapeutic drugs (carboplatin) of the triple-negative breast cancer is enhanced by inhibiting a PI3K-AKT signal channel, and a new regulatory factor is provided for improvement of a cell apoptosis signal channel.

Methods for treating non-small cell lung cancer (NSCLC) include the administration of a combination of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed. The methods are based on tumor mutational burden (TMB) assessment, with specific treatment regimens tailored to the mutational profile of the tumor. When a low tumor mutational burden is detected in a tumor sample, the combination therapy of 2,2'-dithio-bis-ethane sulfonate, carboplatin, and pemetrexed is administered, offering enhanced therapeutic efficacy.

The present invention relates to methods of treating head and neck squamous cell carcinoma (HNSCC), such as metastatic or advanced HNSCC, in a subject in need thereof, comprising administering a therapeutically effective amount of an antibody to the subject, wherein the antibody specifically binds epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-Met) in addition to a PD-(L)1 axis inhibitor (pembrolizumab) and a platinum-based chemotherapy agent (carboplatin). In particular, the EGFR / c-Met antibody is amivantamab.

A device and method are taught for stimulating sympathetic nerves toward mitigating negative impacts to hematopoiesis. An autonomic nerve actuator and stimulator system with a graphic user interface (GUI), controller circuit which converts treatment parameters into a series of Building Block Waveforms (BBW) which are output to Current / Voltage Driver Circuitry (CDC) whose electrical stimulus (ES) outputs are coupled to one or more electrodes and / or electrode arrays positioned proximal specific nerve situations. The use of this in combination with conventional chemotherapy treatments, such as use of carboplatin, was found to significantly enhance hematopoiesis, with improvements in white and red blood cell counts, platelet concentration and hemoglobin concentration, in addition to other measurable characteristics which increased survival rates in the experimental groups tested.

The invention relates to application of O-GlcNAc modified OPG in preparation of drugs for enhancing drug sensitivity of tumor cells. The amino acid sequence of the OPG is shown as SEQ ID NO.1, and O-GlcNAc modification exists at the site S151 of the OPG. According to the invention, the O-GlcNAc modification obviously enhances the stability and activity of the OPG protein and the correlation between the O-GlcNAc modified OPG and the malignant progression of tumors. The method focuses on an O-GlcNAc modification related protein spectrum and identifies and defines a new substrate modified by O-GlcNAc; the invention discloses that O-GlcNAc modified OPG is mediated by membrane protein EHD1 to promote malignant progression of tumors in a manner of promoting a cell cycle axis, and clarifies a novel tumor treatment means, and drug resistance of lung adenocarcinoma tumor cells to carboplatin and pemetrexed can be reversed by breaking an O-GlcNAc modified OPG axis, so that the curative effect of chemical treatment is improved.

The present application relates to a kind of tetravalent platinum complex, nanoparticle and its preparation method and application, the structural formula of the tetravalent platinum complex is as shown in formula I, wherein, cisplatin, carboplatin or oxaliplatin;N is the integer selected from 1-8. The tetravalent platinum complex or the nanoparticle comprising it can be reduced to divalent platinum counterpart under tumor cell environment, and play tumor cell killing effect, can reduce tumor cell drug resistance, enhance the effect of tumor cell killing, have obvious enhanced anti-tumor immune effect.

Described herein are injectable carboplatin formulations, comprising: about 10 mg / mL of carboplatin; and a pharmaceutically acceptable vehicle; wherein the formulation has a pH of from about 5 to about 7; wherein the formulation has a dissolved oxygen level of not less than about 28 ppm; wherein the formulation is filled in a vial at a fill volume of from about 1 mL to about 70 mL in a vial having a capacity of from about 1 mL to about 100 mL; wherein the vial has head space ranging from about 20% to about 82%; and wherein the headspace comprises oxygen gas in an amount effective to maintain a 1,1-cyclobutanedicarboxylic acid level of not more than 1.0%, based on the weight of carboplatin, and a total degradation impurity level at not more than 2.5%, based on the weight of carboplatin, when stored at room temperature for 24 months.

The present invention relates to the technical field of biochemical detection, and discloses a nucleic acid detection composition for non-small cell lung cancer carboplatin resistance screening, the nucleic acid detection composition comprises a specific amplification primer pair of a targeting NFAT2 gene, a TaqMan detection probe, a hot start TaqDNA polymerase and a reaction buffer solution, the reaction buffer solution comprises ectoine and tetramethylammonium chloride, according to the method, carboplatin is blocked by a compact hydrated shell layer formed on the surface of enzyme through ectoine, and the hydrogen bond energy difference between basic groups of nucleic acid large grooves is eliminated by using tetramethylammonium chloride, so that the microcosmic functional phase splitting structure is constructed. Therefore, efficient protection of polymerase activity and regulation and control of primer hybridization specificity are synchronously realized in a single reaction system, and sensitivity and accuracy of drug-resistant gene detection in a complex clinical sample are improved.

The invention relates to an application of a combination of an anti-TROP-2 antibody coupling drug and an anti-PD-L1 antibody or other chemotherapeutic drugs such as carboplatin or cis-platinum and the like in preparation of drugs for preventing and / or treating tumor diseases, and the anti-TROP-2 antibody can be Sacituzumab.

Provided is a method to detect cancer biomarkers, wherein the biomarkers indicate whether a patient will be susceptible to a chemotherapeutic agent.

A method delivers a drug to a target site of internal body tissue for treating cancer. The method provides a chemotherapy drug having a concentration of from about 10 mg / mL to about 40 mg / mL. Also provided is a surgically implantable iontophoresis device including a source electrode and a counter electrode. The iontophoresis device comprises a housing secured to the target tissue and defining a reservoir having an opening. The chemotherapy drug flows through the reservoir at a flow rate of from about 50 μL / min to about 7 mL / min. A localized electrical field is generated by applying a current of between about 1 mA to about 10 mA at the tissue of the target site inducing the chemotherapy drug to permeate the membrane. The method thus delivers by iontophoresis the chemotherapy drug, including gemcitabine hydrochloride and carboplatin, into the tissue of the target site.

Provided include methods, compositions and kits for treating ovarian cancer (e.g., platinum-resistant ovarian cancer) in a subject. The method can comprise administration of a combination of a PLK1 inhibitor and a DNA-damaging agent (e.g., carboplatin or gemcitabine) to the subject in a manner sufficient to inhibit progression of the cancer.

The invention discloses a primary cell and a progeny cell of human brain glioma and application of the primary cell and the progeny cell. The invention provides a human brain glioma primary cell which is a human brain glioma primary cell Glioma-2, and the preservation number of the human brain glioma primary cell Glioma-2 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: C202420. The human brain glioma primary cell Glioma-2 provided by the invention can form clone in soft agar, and shows different drug toxic reactions to common chemotherapeutic drugs (cis-platinum, carboplatin, etoposide, carmostine and irinotecan) for brain glioma. The human brain glioma primary cell Glioma-2 provided by the invention can be used for analyzing the pathogenesis of brain glioma in vitro and in vivo and detecting related characteristics such as drug sensitivity in vitro, and an experimental material closer to clinical tumor biological characteristics is provided for research of human brain glioma.

The disclosure provides antibody-drug conjugates that bind to tissue factor (TF) (e.g, tisotumab vedotin) and its use in methods of treating cancer, such as head and neck squamous cell carcinoma or a gynecological cancer, including in combination with a radiation therapy. The disclosure also provides antibody-drug conjugates that bind to TF for use in combination with an additional chemotherapeutic, such as a platinum-based agent (e.g., carboplatin or cisplatin), including in combination with a radiation therapy, for treating cancer.

The invention discloses a poly (lactic acid-glycolic acid) copolymer composite fiber membrane as well as a preparation method and application thereof. The poly (lactic acid-glycolic acid) copolymer composite fiber membrane provided by the invention comprises a poly (lactic acid-glycolic acid) copolymer fiber matrix, a loaded chemotherapeutic drug and a copper-based metal organic framework, the loaded chemotherapeutic drugs comprise carmustine, carboplatin and etoposide; the copper-based metal organic framework is CuBDC; according to the invention, by optimizing the electrospinning liquid formula and the electrospinning process, the synergistic loading of the PLGA fiber membrane on the water-soluble drug, the hydrophobic drug and the copper-based MOF is successfully realized, and the problems of limited drug loading, short slow release period and single function of the current PLGA drug-loaded fiber membrane are solved.

Anti-tumor platinum drug mineralized protein nanoparticles and a preparation method therefor are disclosed. The anti-tumor platinum-based drug mineralized protein nanoparticles include a platinum drug and a protein. The protein is one or more selected from the group consisting of albumin, transferrin, hemoglobin, and low-density lipoprotein. The platinum drug is cisplatin, iodoplatin, bromoplatin, oxaliplatin, carboplatin, or nedaplatin. A drug loading of the anti-tumor platinum-based drug mineralized protein nanoparticles is 1% to 50%.

The present disclosure relates to the treatment of solid cancers, such as breast cancer, colon cancer, and lung cancer (particularly non-small cell lung cancer (NSCLC)), in human subjects using anti-PD-1 antibodies as monotherapy or as combination therapy with, for example, chemotherapy and / or surgery. The treatments provided may be a combination of tiralizumab and chemotherapy prior to surgery, using different doses of tiralizumab in an auxiliary stage after surgery. Administration regimens may include administration of 200 mg of an anti-PD-1 antibody (e.g., tiralizumab) (e.g., every three weeks) followed by tumor resection, followed by administration of 400 mg of the anti-PD-1 antibody (e.g., every six weeks). Furthermore, the chemotherapy may be platinum-based (e.g., carboplatin and / or cis-platinum), and may further include pemetrexed (e.g., for non-squamous cancer) or paclitaxel (e.g., for squamous cancer).